Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 2Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 16Plasma cell 11Other hematologic neoplasm 9Gastrointestinal 4CNS 4Sarcoma 3Dermatologic 3Myeloid 2Genitourinary 2Endocrine 2Breast 2Thoracic 1NET 1Head & Neck 1

Conditions

Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Carcinoma, Renal Cell 1Adenocarcinoma 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Panobinostat × Genitourinary × Clear all
NCT00550277 2021-11-23

LBH589 Treatment for Refractory Clear Cell Renal Carcinoma

SCRI Development Innovations, LLC

Phase 2 Completed
20 enrolled 7 charts
Genitourinary

Carcinoma, Renal Cell

NCT00667862 2021-06-21

Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer

Novartis

Phase 2 Completed
35 enrolled 8 charts
Genitourinary

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡